| Literature DB >> 33008924 |
Genta Kakiyama1, Dalila Marques2, Rebecca Martin3, Hajime Takei4, Daniel Rodriguez-Agudo2, Sandra A LaSalle5, Taishi Hashiguchi6, Xiaoying Liu7, Richard Green7, Sandra Erickson8, Gregorio Gil9, Michael Fuchs2, Mitsuyoshi Suzuki10, Tsuyoshi Murai11, Hiroshi Nittono4, Phillip B Hylemon12, Huiping Zhou12, William M Pandak13.
Abstract
NAFLD is an important public health issue closely associated with the pervasive epidemics of diabetes and obesity. Yet, despite NAFLD being among the most common of chronic liver diseases, the biological factors responsible for its transition from benign nonalcoholic fatty liver (NAFL) to NASH remain unclear. This lack of knowledge leads to a decreased ability to find relevant animal models, predict disease progression, or develop clinical treatments. In the current study, we used multiple mouse models of NAFLD, human correlation data, and selective gene overexpression of steroidogenic acute regulatory protein (StarD1) in mice to elucidate a plausible mechanistic pathway for promoting the transition from NAFL to NASH. We show that oxysterol 7α-hydroxylase (CYP7B1) controls the levels of intracellular regulatory oxysterols generated by the "acidic/alternative" pathway of cholesterol metabolism. Specifically, we report data showing that an inability to upregulate CYP7B1, in the setting of insulin resistance, results in the accumulation of toxic intracellular cholesterol metabolites that promote inflammation and hepatocyte injury. This metabolic pathway, initiated and exacerbated by insulin resistance, offers insight into approaches for the treatment of NAFLD.Entities:
Keywords: cholesterol toxicity; inflammation; liver injury; nonalcoholic fatty liver; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; oxysterol; oxysterol 7α-hydroxylase
Year: 2020 PMID: 33008924 PMCID: PMC7707165 DOI: 10.1194/jlr.RA120000924
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922